QGEN Aug 2024 30.000 put
| Previous Close | 0.4300 |
| Open | N/A |
| Bid | 0.0000 |
| Ask | 1.3000 |
| Strike | 30.00 |
| Expire Date | 2024-08-16 |
| Day's Range | 0.4300 - 0.4300 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 1 |
ReutersQiagen eyes sales growth of 7% per year until 2028
Diagnostics company Qiagen said on Monday it was targeting 7% currency-adjusted sales growth per year until 2028 on lab testing machines for infections and cancer, as it maps out its post-pandemic strategy. Qiagen has said it will return to growth in adjusted earnings this year, recovering from last year's drop in profit when demand for coronavirus lab tests plunged. "Between life sciences and clinical application, our market is growing between 4% and 6%, so saying 7% means outpacing the market and therefore taking market share," CEO Thierry Bernard told Reuters.
ZacksQIAGEN (QGEN) Debuts dPCR Microbial DNA Detection Assays
QIAGEN (QGEN) launches new QIAcuity dPCR assays for microbial applications, enhancing infectious disease research and surveillance.
GlobeNewswireQIAGEN announces 2028 strategy for solid profitable growth
Hosts Capital Markets Day event in New York to outline strategy anchored by sharpened focus on growth pillars set to drive about 7% CER sales CAGR from 2024-2028 // Targeting at least 31% CER adjusted operating income margin in 2028 from portfolio streamlining (including NeuMoDx decision), operational efficiency gains and digitization // Ensuring disciplined capital allocation with high level of R&D and digital investments, focus on value-creating M&A opportunities and plans to return at least $
